New hepatitis C drug shows potential in phase 2 trials

"Despite recent advances, the current hepatitis C treatment regimen is burdensome on the patient and prone to adverse events," said Patrick Marcellin, lead study author from the Service d'Hépatologie and Inserm CRB3, Hôpital Beaujon, APHP University of Paris. "The promising results from this study offer hope that danoprevir can improve the quality of life for patients suffering from this disease."

Investigators conducted a phase 2, randomized, placebo-controlled study and found that, within just one week of treatment, the addition of danoprevir to the current treatment regimen (peginterferon alfa-2a/ribavirin) led to reductions in levels of hepatitis C virus in the blood. Overall, danoprevir was well tolerated and demonstrated an 85 percent sustained virologic response rate (or no detectable virus in the patient's blood after six months).

Importantly, 79 percent of patients who added danoprevir to their treatment regimen achieved an early virologic response and were eligible for a shortened treatment schedule.

Studies of lower doses of danoprevir on top of the current standard of care, to reduce overall danoprevir exposure while maintaining the drug's effectiveness, are underway. Interim effectiveness and safety data are promising.

Hepatitis C is a serious liver disease caused by the hepatitis C virus, which is spread through direct contact with the blood of infected people and ultimately affects the liver. Chronic hepatitis C can lead to serious and life-threatening liver problems, including liver damage, cirrhosis, liver failure or liver cancer. Though many people with hepatitis C may not experience symptoms, others may have symptoms such as fatigue, fever, jaundice and abdominal pain. For more information on hepatitis, please read the AGA brochure "Understanding Hepatitis."